Compare ATYR & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | CGO |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 112.9M |
| IPO Year | 2015 | N/A |
| Metric | ATYR | CGO |
|---|---|---|
| Price | $0.75 | $12.12 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 34.7K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $7.90 |
| 52 Week High | $7.29 | $10.93 |
| Indicator | ATYR | CGO |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 66.26 |
| Support Level | $0.69 | $11.80 |
| Resistance Level | $0.74 | $12.10 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 67.87 | 99.12 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.